Last update Feb. 19, 2019
Likely Compatibility
We do not have alternatives for C1105 H1770 N318 O336 S26.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
C1105 H1770 N318 O336 S26 is Choriogonadotropin Alfa in Molecular formula.
Is written in other languages:C1105 H1770 N318 O336 S26 is also known as
C1105 H1770 N318 O336 S26 belongs to this group or family:
Main tradenames from several countries containing C1105 H1770 N318 O336 S26 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 25.720 | daltons |
VD | 0.9 | l/Kg |
T½ | 29 ± 6 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is the synthetic form of the natural human chorionic gonadotropin (hCG) hormone, produced by recombinant DNA technology.
Administration by subcutaneous injection.
Indicated to stimulate ovulation in assisted reproduction techniques.
Since the last update we have not found published data on its excretion in breastmilk.
Its high molecular weight makes it very unlikely it will transfer into milk in significant quantities.
Due to its protein nature it is inactivated in the gastrointestinal tract, not being absorbed, so its oral bioavailability is practically nil, except in premature babies and the immediate neonatal period when there may be greater intestinal permeability.
May cause increased prolactin and galactorrhea (Mendes 2001).
No adverse effects have been recorded in infants.
In infertility treatments, the possible theoretical anovulatory effect of frequent on demand breastfeeding must be taken into account.
See below the information of these related products: